Current Report Filing (8-k)
June 27 2017 - 4:32PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM
8-K
Current
Report
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event Reported): June 27, 2017
HISTOGENICS CORPORATION
(Exact Name of Registrant as Specified in its Charter)
|
|
|
|
|
Delaware
|
|
001-36751
|
|
04-3522315
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification Number)
|
830 Winter Street, 3rd Floor
Waltham, Massachusetts 02451
(781)
547-7900
(Addresses, including zip code, and telephone numbers, including area code, of principal executive offices)
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions (see General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or
Rule 12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this
chapter).
Emerging growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the
Exchange Act. ☐
On June 27, 2017, Histogenics Corporation (Histogenics) issued a press
release announcing that it has completed enrollment of its Phase 3 clinical trial of NeoCart®, an investigational product designed to repair and replace damaged cartilage, initially in the knee.
The press release is attached as Exhibit 99.1 to this Current Report on Form
8-K
and incorporated herein by reference.
Item 9.01.
|
Financial Statements and Exhibits.
|
|
|
|
Exhibit
No.
|
|
Description
|
|
|
99.1
|
|
Press Release of Histogenics Corporation dated June 27, 2017.
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
Date: June 27, 2017
|
|
|
|
HISTOGENICS CORPORATION
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Adam Gridley
|
|
|
|
|
|
|
Adam Gridley
|
|
|
|
|
|
|
President and Chief Executive Officer
|
EXHIBIT INDEX
|
|
|
Exhibit
No.
|
|
Description
|
|
|
99.1
|
|
Press Release of Histogenics Corporation dated June 27, 2017.
|
Histogenics (NASDAQ:HSGX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Histogenics (NASDAQ:HSGX)
Historical Stock Chart
From Sep 2023 to Sep 2024